Erasca Shares Drop 9% to $15.54 After Revolution Pancreatic Cancer Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy ERAS?
Erasca drops 9% to $15.54 after Revolution pancreatic cancer data
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 21.710
Low
2.00
Averages
5.50
High
11.00
Current: 21.710
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revolution's Cancer Drug Shows Promising Results in Trials
- Clinical Trial Results: Revolution's experimental cancer drug daraxonrasib demonstrated statistically significant improvements in progression-free survival and overall survival in patients with metastatic pancreatic ductal adenocarcinoma, with a median survival of 13.2 months compared to 6.7 months for chemotherapy, indicating substantial clinical relevance.
- Market Reaction: Following the announcement, Revolution's shares surged by 41%, reflecting strong market enthusiasm for its research findings, with RBC Capital labeling the drug a 'game changer', potentially attracting more investor interest in the company.
- Competitor Dynamics: Erasca's shares fell by 7% after the positive data from Revolution, despite its own focus on developing therapies for pancreatic cancer, indicating that market confidence in Revolution's results may negatively impact Erasca's outlook.
- Analyst Ratings: While Jefferies maintained a 'Buy' rating and a $21 price target for Erasca, the lack of significant improvement in market expectations suggests that the heightened focus on Revolution could overshadow Erasca's future performance.
See More
Erasca Inc Shares Surpass Analyst Target Price
- Stock Performance: Erasca Inc's shares recently surpassed the 12-month analyst target price of $17.70, currently trading at $17.81, indicating increased market confidence in the company.
- Analyst Reactions: When a stock reaches its target price, analysts may either downgrade their valuation or raise their target, reflecting differing views on the company's fundamental developments, which can influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, the average target price for Erasca Inc is $17.70, but there is significant variance with a low target of $2.00 and a high target of $25.00, resulting in a standard deviation of $6.377, highlighting diverse market expectations.
- Investor Signal: The stock's rise above the target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is justified or if it is time to take profits to mitigate risk.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
Erasca CMO Sells Shares Under 10b5-1 Plan
- Transaction Overview: On March 4, 2026, Erasca's Chief Medical Officer, Morris Shannon, exercised and sold 20,000 shares of common stock for approximately $301,000 at an average price of $15.04 per share, reflecting routine compensation management for executives.
- Ownership Change Analysis: This transaction reduced Shannon's direct holdings to zero; however, this does not indicate a loss of investment in the company as she retains 515,800 options, ensuring continued exposure to Erasca's future.
- Trading Plan Context: The stock sale was executed under a pre-established 10b5-1 trading plan set in June 2024, indicating that the transaction was planned and compliant with corporate governance, mitigating market concerns regarding her ownership changes.
- Company Strategic Positioning: Erasca focuses on developing precision oncology therapeutics for RAS/MAPK pathway-driven cancers, leveraging a robust pipeline and deep expertise in molecular oncology to address significant unmet medical needs and enhance its competitive edge in the rapidly evolving oncology market.
See More
Erasca CMO Sells Shares in SEC Filing
- Transaction Overview: Morris Shannon, CMO of Erasca, reported the sale of 20,000 shares of common stock valued at approximately $301,000 in an SEC Form 4 filing, indicating a strategic liquidity management approach.
- Direct Ownership Change: Following this transaction, Shannon's direct common stock holdings dropped to zero; however, he retains rights to acquire up to 515,800 shares through stock options, highlighting significant future equity exposure.
- Market Reaction Analysis: The reduction of Shannon's direct holdings to zero does not imply pessimism about the company's outlook, but rather reflects routine compensation management under a pre-established 10b5-1 trading plan from June 2024, reinforcing confidence in Erasca's future.
- Company Background and Outlook: Erasca focuses on developing precision oncology therapeutics targeting the RAS/MAPK pathway, with future revenue expected from drug approvals and licensing agreements, achieving a market capitalization of $4.71 billion, showcasing its competitive edge in the rapidly evolving oncology market.
See More
Erasca Reports Q4 2025 Financial Results with Reduced Losses
- Reduced Net Loss: Erasca reported a net loss of $29.1 million for Q4 2025, translating to a loss of $0.10 per share, which is an improvement from the $32.2 million loss and $0.11 per share in Q4 2024, indicating initial success in cost management efforts.
- Annual Loss Overview: For the full year 2025, the company recorded a net loss of $124.5 million, or $0.44 per share, a significant reduction from the $161.7 million loss and $0.69 per share in 2024, reflecting gradual improvements in financial health.
- Stock Offering Announcement: Erasca has priced a $225 million stock offering at $10 per share, aimed at strengthening its capital base to support future R&D and operational needs, demonstrating the company's confidence in the market.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest and highlighting its active presence in the industry along with future growth potential.
See More
Revolution's Cancer Drug Shows Promising Results in Trials
- Clinical Trial Results: Revolution's experimental cancer drug daraxonrasib demonstrated statistically significant improvements in progression-free survival and overall survival in patients with metastatic pancreatic ductal adenocarcinoma, with a median survival of 13.2 months compared to 6.7 months for chemotherapy, indicating substantial clinical relevance.
- Market Reaction: Following the announcement, Revolution's shares surged by 41%, reflecting strong market enthusiasm for its research findings, with RBC Capital labeling the drug a 'game changer', potentially attracting more investor interest in the company.
- Competitor Dynamics: Erasca's shares fell by 7% after the positive data from Revolution, despite its own focus on developing therapies for pancreatic cancer, indicating that market confidence in Revolution's results may negatively impact Erasca's outlook.
- Analyst Ratings: While Jefferies maintained a 'Buy' rating and a $21 price target for Erasca, the lack of significant improvement in market expectations suggests that the heightened focus on Revolution could overshadow Erasca's future performance.
See More
Erasca Inc Shares Surpass Analyst Target Price
- Stock Performance: Erasca Inc's shares recently surpassed the 12-month analyst target price of $17.70, currently trading at $17.81, indicating increased market confidence in the company.
- Analyst Reactions: When a stock reaches its target price, analysts may either downgrade their valuation or raise their target, reflecting differing views on the company's fundamental developments, which can influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, the average target price for Erasca Inc is $17.70, but there is significant variance with a low target of $2.00 and a high target of $25.00, resulting in a standard deviation of $6.377, highlighting diverse market expectations.
- Investor Signal: The stock's rise above the target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is justified or if it is time to take profits to mitigate risk.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
Erasca CMO Sells Shares Under 10b5-1 Plan
- Transaction Overview: On March 4, 2026, Erasca's Chief Medical Officer, Morris Shannon, exercised and sold 20,000 shares of common stock for approximately $301,000 at an average price of $15.04 per share, reflecting routine compensation management for executives.
- Ownership Change Analysis: This transaction reduced Shannon's direct holdings to zero; however, this does not indicate a loss of investment in the company as she retains 515,800 options, ensuring continued exposure to Erasca's future.
- Trading Plan Context: The stock sale was executed under a pre-established 10b5-1 trading plan set in June 2024, indicating that the transaction was planned and compliant with corporate governance, mitigating market concerns regarding her ownership changes.
- Company Strategic Positioning: Erasca focuses on developing precision oncology therapeutics for RAS/MAPK pathway-driven cancers, leveraging a robust pipeline and deep expertise in molecular oncology to address significant unmet medical needs and enhance its competitive edge in the rapidly evolving oncology market.
See More
Erasca CMO Sells Shares in SEC Filing
- Transaction Overview: Morris Shannon, CMO of Erasca, reported the sale of 20,000 shares of common stock valued at approximately $301,000 in an SEC Form 4 filing, indicating a strategic liquidity management approach.
- Direct Ownership Change: Following this transaction, Shannon's direct common stock holdings dropped to zero; however, he retains rights to acquire up to 515,800 shares through stock options, highlighting significant future equity exposure.
- Market Reaction Analysis: The reduction of Shannon's direct holdings to zero does not imply pessimism about the company's outlook, but rather reflects routine compensation management under a pre-established 10b5-1 trading plan from June 2024, reinforcing confidence in Erasca's future.
- Company Background and Outlook: Erasca focuses on developing precision oncology therapeutics targeting the RAS/MAPK pathway, with future revenue expected from drug approvals and licensing agreements, achieving a market capitalization of $4.71 billion, showcasing its competitive edge in the rapidly evolving oncology market.
See More
Erasca Reports Q4 2025 Financial Results with Reduced Losses
- Reduced Net Loss: Erasca reported a net loss of $29.1 million for Q4 2025, translating to a loss of $0.10 per share, which is an improvement from the $32.2 million loss and $0.11 per share in Q4 2024, indicating initial success in cost management efforts.
- Annual Loss Overview: For the full year 2025, the company recorded a net loss of $124.5 million, or $0.44 per share, a significant reduction from the $161.7 million loss and $0.69 per share in 2024, reflecting gradual improvements in financial health.
- Stock Offering Announcement: Erasca has priced a $225 million stock offering at $10 per share, aimed at strengthening its capital base to support future R&D and operational needs, demonstrating the company's confidence in the market.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest and highlighting its active presence in the industry along with future growth potential.
See More
